LAUSR

and better selection of treatment modalities (surgical vs. nonsurgical). As with other noninvasive technologies, OCT is not perfect and carries a potential ‘blind-spot’: it lacks histology-like resolution that translates into a low specificity (~60%), as some tumours may look similar under OCT. How can we overcome this limitation? By adding the benefit of another noninvasive device with higher specificity such as reflectance confocal microscopy (RCM). RCM provides better diagnostic accuracy than OCT because of higher resolution but at the expense of depth (maximum 200 lm). Merging the advantages of both into a single device would be beneficial. A combined RCM–OCT device was recently reported, showing good diagnostic accuracy and depth measurement for the ‘three-dimensional’ detection of BCC (Fig. 1). Noninvasive imaging is helping us manage patients with BCC to an extent we never imagined before: by diagnosing, delineating margins, guiding choice of surgical vs. nonsurgical treatments, detecting residual tumour to locate biopsy site and monitoring treatment response. Stay tuned, as BCC management evolves into a streamlined approach!